Development of Foxy5, a WNT5A mimicking peptide, in GI cancers

Ramon Salazar, MD, PhD, Institut Català D'Oncologia, Barcelona, Spain, gives an overview of the mechanism of action of Foxy5, a first-in-class peptide that mimics WNT5A. The novel drug will aim to inhibit the migration of tumor cells and thus prevent metastasis in patients with gastrointestinal (GI) cancers. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.